Paragon 28

Paragon 28, Inc. engages in operation of an orthopedic foot and ankle company. Its products include bone graft harvest system, bone marrow aspirate kits, and soft tissue fixation system. The company was founded by Albert DaCosta, Frank Bono, Jim Riegler and Lee Rosenthal in 2010 and is headquartered in Englewood, CO.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Paragon 28 reports strong revenue growth and strategic initiatives outlook

Paragon 28 delivered robust financial results in Q4 2022 and full-year 2022, driven by strong revenue growth in the U.S. and international markets.
While facing challenges in achieving profitability and commercializing new technologies, the company's focus on innovation and market expansion presents opportunities for future growth.
With a solid liquidity position and strategic initiatives in place, Paragon 28 is well-positioned to capitalize on market opportunities and drive continued performance.
Investors can look forward to the company's projected revenue growth in 2023 and advancements in technology adoption for improved patient outcomes.

Paragon 28 reports record Q1 revenue, eyes global growth opportunities

Paragon 28 delivered robust financial performance in Q1 2023, driven by strong revenue growth in the U.S. and internationally. While challenges in achieving profitability persist, the company's strategic focus on product development and global market expansion positions it for continued success. Opportunities for growth include optimizing sales force efficiency, launching new products, and capitalizing on international market strength.

Paragon 28 reports strong Q2 performance, eyes international expansion

Paragon 28's Q2 2023 earnings call reflects robust financial performance, driven by international growth and successful product launches.
While facing supply chain challenges and anticipating a growth slowdown, the company remains focused on expanding its market reach and product offerings.
Investments in key markets and a strategic focus on emerging growth drivers underscore Paragon 28's commitment to sustained revenue growth.
Prudence in guidance and operational planning amidst uncertainties highlights the company's proactive approach to managing challenges and seizing opportunities.

Paragon 28 reports steady Q3 growth amidst supply chain challenges

Paragon 28's Q3 2023 earnings call highlighted steady revenue growth, product innovation, and strategic investments driving performance.
While facing supply chain challenges and billing day impacts, the company's focus on market-specific strategies and surgeon training remains a strength.
Securing a new credit facility and reaffirming revenue guidance underscore Paragon 28's commitment to future growth and market leadership.

Paragon 28 reports robust Q4 performance, eyes growth in 2024

Paragon 28's strong performance in Q4 2023, coupled with expectations for growth in 2024, positions the company well for the future. Despite challenges like supply chain issues, the company's focus on innovation and market expansion presents significant opportunities. By maintaining accountability and leveraging market opportunities, Paragon 28 aims to drive continued success.

Paragon 28 reports record Q1 revenue, eyes growth opportunities

Paragon 28's Q1 2024 performance reflects strong revenue growth and strategic product launches.
While facing challenges like negative cash flow and increased SG&A expenses, the company remains optimistic.
Opportunities lie in upcoming product launches, market expansion, and engagement with investors.
Overall, Paragon 28's resilience and growth trajectory position it well for future success in the medical devices sector.

Paragon 28 reports record revenue and positive EBITDA in Q3

Paragon 28's Q3 2024 performance reflects strong revenue growth, product innovation, and a milestone in positive adjusted EBITDA post-IPO.
The company's emphasis on operational efficiency and cost optimization positions it well for sustained profitability and growth.
While facing challenges in cash flow and margin stabilization, Paragon 28 has opportunities to capitalize on its strengths and drive further expansion.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Paragon 28, Inc. (“Paragon” or the “Company”) (NYSE: FNA) investors concerning the Company's possible violations of the federal securities laws. If you suffered a loss on your Paragon investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, y.

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Paragon 28, Inc. (FNA) on Behalf of Investors

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Paragon 28, Inc. (“Paragon” or the “Company”) (NYSE: FNA) investors concerning the Company's possible violations of federal securities laws. On July 30, 2024, after market hours, Paragon disclosed that the Company's previously issued financial statements from 2023 and 2024 should no longer be relied upon “due to errors in such financial statements” related to “accounting” and would therefore r.

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Paragon 28, Inc. (FNA) on Behalf of Investors

SAN DIEGO, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP is investigating whether Paragon 28, Inc. (NYSE: FNA) or any of its executive officers or others violated securities laws by misrepresenting or failing to timely disclose material, adverse information to investors.

Johnson Fistel Law Firm Begins Investigation into Paragon 28 and Urges Shareholders with Losses to Reach Out for More Information

NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Paragon 28, Inc. (NYSE: FNA) resulting from allegations that Paragon 28 may have issued materially misleading business information to the investing public. So what: If you purchased Paragon 28 securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

Rosen Law Firm Encourages Paragon 28, Inc. Investors to Inquire About Securities Class Action Investigation – FNA

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Paragon 28, Inc. (“Paragon” or the “Company”) (NYSE: FNA) on behalf of investors concerning the Company's possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. On July 30, 2024, after market hours, Paragon disclosed that the Company's previously issued financial statements from 2023 and 2024 should no longer be relied upon “due to errors.

The Law Offices of Frank R. Cruz Announces Investigation of Paragon 28, Inc. (FNA) on Behalf of Investors

Ideaya Biosciences Inc

DALLAS--(BUSINESS WIRE)--Generational Group, a leading mergers and acquisitions advisory firm for privately held businesses, is pleased to announce the sale of its client, Schuylkill Haven Casket Company and Columbia Caskets Corp., to Victoriaville & Co. The acquisition closed July 9, 2024. Located in Schuylkill Haven, Pennsylvania, Haven Line Industries (became Haven Line industries in 1975 with the acquisition of Columbia Caskets Corp.) was established in 1919 and includes both Schuylkill.

Generational Group Advises Schuylkill Haven Casket Company and Columbia Caskets Corp. in its sale to Victoriaville & Co.

ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA) (“PARAGON”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced it will report financial results for the second quarter 2024 after market close on Thursday, August 8, 2024. The Company's management will webcast a corresponding conference call beginning at 4:30 p.m. Eastern Time / 2:30 p.m. Mountain Time. Investors interested in listening to the conference call may do so by dialin.

Paragon 28 to Report Second Quarter 2024 Financial Results on August 8, 2024

Paragon 28, Inc. (NYSE:FNA ) Q1 2024 Earnings Conference Call May 8, 2024 4:30 PM ET Company Participants Matthew Brinckman - Senior Vice President, Strategy and IR Albert DaCosta - Chairman, CEO, Co Founder Krissy Wright - Interim Chief Financial Officer Conference Call Participants Matthew O'Brien - Piper Sandler & Co. George Sellers - Stephens Inc. Craig Bijou - BofA Securities Mike Matson - Needham & Company, LLC Justin Lin - William Blair & Company LLC Dave Turkaly - Citizens Financial Group Caitlin Cronin - Canaccord Genuity Operator Good afternoon. And welcome to Paragon 28's First Quarter 2024 Earnings Conference Call.

Paragon 28, Inc. (FNA) Q1 2024 Earnings Call Transcript

ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA) (“Paragon 28” or "Company”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today reported financial results for the quarter ended March 31, 2024, and reaffirmed its 2024 net revenue guidance. First Quarter 2024 Financial Results Consolidated net revenue for the first quarter of 2024 was a record $61.1 million, representing 17.4% reported and constant currency growth over the first qua.

Paragon 28 Reports First Quarter 2024 Financial Results and Reaffirms 2024 Net Revenue Guidance

ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced that Albert DaCosta, Chairman and CEO, and Krissy Wright, Interim CFO, will participate in a fireside chat at the Bank of America Securities 2024 Healthcare Conference on Tuesday, May 14, 2024, at 5:00 p.m. Pacific Time / 6:00 p.m. Mountain Time. A live webcast, as well as the archived recording, will be available on the i.

Paragon 28 to Present at the Bank of America Securities 2024 Healthcare Conference

OXFORD, United Kingdom, April 04, 2024 (GLOBE NEWSWIRE) -- OrganOx, a medical device company which is changing the paradigm in liver transplantation in the US and Europe with its groundbreaking normothermic machine perfusion technology, today announces that Stephen (Steve) M. Deitsch will be joining OrganOx as Chief Financial Officer (“CFO”) on April 8, 2024.

Appointment of Stephen M. Deitsch as new Chief Financial Officer

Redfin

OTTAWA, Ontario--(BUSINESS WIRE)--NeuroStreet acquires TickBlaze to elevate trading tech, promising transformative solutions in the industry.

NeuroStreet To Transform Trading Technology With Tickblaze Acquisition

ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA), (“Paragon 28” or “the Company”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced that Stephen Deitsch, Chief Financial Officer (“CFO”), has notified the Company of his intent to pursue an opportunity with OrganOx Limited, a commercial stage UK-based medical device company focused on therapeutic applications of isolated organ perfusion. Mr. Deitsch will depart from the C.

Paragon 28 Announces CFO Transition, Provides Preliminary Unaudited Net Revenue for First Quarter 2024, and Reaffirms Net Revenue Guidance for Fiscal Year 2024

The dynamic functionality of Paragon 28's (FNA) Grappler R3INFORCE System sets it apart from traditional static repair systems, offering a more physiological and anatomical reconstruction option.

Paragon 28 (FNA) Expands Syndesmotic Repair Line With New Launch

ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA), is pleased to announce the launch of the Grappler® R3INFORCE™ Extraosseous Repair System designed to restore stability to the anterior and posterior ligaments surrounding the ankle during fibula fracture repairs and high ankle sprains. Upon determination of syndesmotic instability, the Grappler® R3INFORCE™ Anchors are placed in plate holes or other anatomic locations where pre-loaded suture tape can be routed and tensioned to addr.

Paragon 28 Adds to Suite of Novel Syndesmosis Repair Solutions with Launch of Grappler® R3INFORCE™ Extraosseous Repair System

Paragon 28, Inc. (FNA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Paragon 28, Inc. (FNA) Moves 16.2% Higher: Will This Strength Last?

Paragon 28, Inc. (FNA) Q4 2023 Earnings Call Transcript

ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA) (“Paragon 28” or “Company”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today reported financial results for the quarter and year ended December 31, 2023 and provided 2024 Net Revenue guidance. Fourth Quarter and Full Year 2023 Financial Results Consolidated net revenue for the fourth quarter of 2023 was $60.6 million, representing 17.6% and 17.3% reported and constant currency gro.

Paragon 28 Reports Fourth Quarter and Full Year 2023 Financial Results and Provides 2024 Net Revenue Guidance

ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced that Albert DaCosta, Chairman and CEO and Steve Deitsch, CFO will participate in a fireside chat at the CG 2024 Musculoskeletal Conference on Monday, February 12, 2024, at 1:00 p.m. Pacific Time / 2:00 p.m. Mountain Time. A live webcast, as well as the archived recording, will be available on the investor relations section.

Paragon 28 to Present at the CG 2024 Musculoskeletal Conference

ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA) (“PARAGON”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced it will report financial results for the fourth quarter and full year 2023 after market close on Thursday, February 29, 2024. The company's management will webcast a corresponding conference call beginning at 4:30 p.m. Eastern Time / 2:30 p.m. Mountain Time. Investors interested in listening to the conference call ma.

Paragon 28 To Report Fourth Quarter and Full Year 2023 Financial Results on February 29, 2024

ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA) is pleased to announce the launch of the PRECISION® MIS Bunion System, which allows surgeons to complete a distal metatarsal osteotomy using a minimally invasive (MIS) surgical technique. The system features an outrigger designed for controlled tri-planar correction including translation and derotation of the metatarsal head and adjustment of the distal metatarsal articular angle. Instrumentation is also provided to facilitate a fr.

Paragon 28 Launches PRECISION® MIS Bunion System Offering Surgeons a Guided Minimally Invasive Surgical Solution for Treating Patients with Bunions

ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA) is proud to announce a novel solution in modernizing foot and ankle surgery with the launch of its FJ2000™ Power Console and Burr System designed for a wide range of minimally invasive and open procedures in the foot and ankle. The FJ2000™ Power Console and Burr System is highly versatile and designed for quick and efficient setup at the outset of each procedure. The System has three pre-set options, including a low speed, high tor.

Paragon 28 Announces the Launch of the FJ2000™ Power Console and Burr System Designed Specifically for Foot and Ankle Procedures

ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA), is pleased to announce the launch of the Mister Tendon™ System which allows surgeons to perform a distal cut of the flexor hallucis longus (“FHL”) or flexor digitorum longus (“FDL”) tendon through a minimally invasive incision, harvesting a working length of tendon suitable for tendon transfer procedures. Use of this instrumentation through a minimally invasive approach, is designed to allow for better healing and quicker recovery.

Paragon 28 Launches the Mister Tendon™ Harvester System – The First and Only Minimally Invasive Harvesting System for FHL and FDL Tendon Transfer Procedures

ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA) (“Paragon 28” or “P28”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced a range of its preliminary unaudited net revenue for the fourth quarter and full year ended December 31, 2023. Preliminary unaudited net revenue for the fourth quarter of 2023 is expected to be in a range of $60.3 to $60.6 million, representing reported growth of approximately 17% to 18% compared to.

Paragon 28 Announces Preliminary Unaudited Revenue for Fourth Quarter and Full Year 2023

ENGLEWOOD, Co.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA), is thrilled to announce the launch of the Grappler® Knotless Anchor System and Bridgeline™ Tape, enhancing the Company's position in the fast-growing foot and ankle specific soft tissue market in 2024 and beyond. Both the Grappler® Knotless Anchor System and Bridgeline™ Tape are highly complementary to a broad range of Paragon 28's existing hardware products with several applications spanning multiple foot and ankle indications. The.

News for Paragon 28 Stock (FNA)